Recent Updates
Recently added Catalysts

CT204V-CD19 × CD20

Phase 1/2

Relapsed or Refractory B-Cell Malignancies | Small Molecules | Other |AstraZeneca PLC|Trials Updated: Nov 12, 2026

CT204V-CD19 × CD20 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Nov 2026

CT204V-CD19 × CD20 target and mechanism

ModalitySmall Molecules

Also known as CT204V

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment160

FDA Designations

No designations recorded

CT204V-CD19 × CD20 clinical trials

CT204V-CD19 × CD20 · 1 trial · 1 indication

Phase 1/2 1
NCT07932496A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refractory B-Cell Malignancies.Relapsed or Refractory B-Cell Malignancies
NOT YET_RECRUITING160 Analytics
PHASE1/PHASE2NOT YET_RECRUITING
A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refractory B-Cell Malignancies.
Relapsed or Refractory B-Cell Malignancies
NCT07932496160
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Adverse Events(AEs)/Serious Adverse Events (SAEs), Phase 1 of the study.
Up to 15 years

Incidence and severity of Adverse Events(AEs)/Serious Adverse Events (SAEs), Phase 1 of the study.

Number of Dose-Limiting Toxicities (DLTs) events during dose escalation, Phase 1 of the study.
Up to 28 days.

Incidence of Dose-Limiting Toxicities (DLTs) during dose escalation, Phase 1 of the study.

Number of AEs leading to dose reduction, withdrawal, interruption, Phase 1 of the study.
Up to 1 year.

Incidence of AEs leading to dose reduction, withdrawal, interruption, Phase 1 of the study.

Number of AEs leading to death, Phase 1 of the study.
Up to 15 years

Incidence of AEs leading to death, Phase 1 of the study.

Number of AESI (adverse events of special interest), Phase 1 of the study.
Up to 15 years

Incidence of AESI (adverse events of special interest), Phase 1 of the study.

Objective Response Rate (Complete Response+Partial Response) per Lugano Classification, Phase 2 of the study.
Up to 24 months.

To assess the efficacy based on ORR (CR+PR) events.

Complete Response (CR) rate, Phase 2 of the study.
Up to 24 months.

To assess the efficacy based on CR rate.

Best Overall Response (BOR), Phase 2 of the study.
Up to 24 months.

To assess the efficacy based on BOR rate.

Duration of Response (DoR), Phase 2 of the study.
Up to 24 months.

To assess the efficacy based on DoR rate.

Duration of Complete Response (DoCR), Phase 2 of the study.
Up to 24 months.

To assess the efficacy based on DoCR rate.

Secondary Endpoints

Objective Response Rate (Complete Response+Partial Response) per Lugano Classification, Phase 1 of the study.
Up to 24 months post-infusion.
Viral vector PK parameter AUClast, Phase 1 of the study.
Up to 24 months post-infusion.
Cellular Kinetics (CK) of CT204V CAR transgene parameter AUC0-28/AUClast, Phase 1 of the study.
Up to 24 months post-infusion.
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CT204V-CD19 × CD20EXPERIMENTALParticipants will receive CT204V-CD19 × CD20, an In Vivo Lentiviral Vector Gene Therapy, generating dual targeting anti-CD19/CD20 Chimeric Antigen Receptor (CAR)-T cells.

Interventions

NameTypeDescription
CT204V-CD19 × CD20DRUGExperimental
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * \* Participants must be at least 18 years of age. * \* Confirmed expression of CD19 and/or CD20. * \* Histologically confirmed and measurable disease for all disease subtypes. * \* ECOG performance status 0 or 1. * \* Adequate organ and bone marrow function. * \* Body weight o...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 12, 2026NCT07932496NEW_TRIAL: changed
LOWNov 12, 2026NCT07932496NEW_TRIAL: changed

Explore more on BiopharmaWatch

AstraZeneca PLC (AZN)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with CCompanies A to ZEvery biotech and pharma company we track